Connor, Clark & Lunn Investment Management (CC&L)
ALNY icon

Connor, Clark & Lunn Investment Management (CC&L)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-73,320
Closed -$20.2M – 1397
2024
Q3 		$20.2M Buy
73,320
+13,422
+22% +$3.49M 0.1% 169
2024
Q2 		$14.6M Buy
59,898
+44,455
+288% +$7.02M 0.06% 228
2024
Q1 		$2.31M Buy
+15,443
New +$2.58M 0.01% 631
2023
Q2 		– Sell
-12,901
Closed -$2.58M – 1298
2023
Q1 		$2.58M Buy
12,901
+11,661
+940% +$2.45M 0.01% 502
2022
Q4 		$295K Buy
+1,240
New +$264K ﹤0.01% 981
2021
Q3 		– Sell
-8,964
Closed -$1.52M – 1023
2021
Q2 		$1.52M Sell
8,964
-6,092
-40% -$892K 0.01% 600
2021
Q1 		$2.13M Buy
15,056
+4,683
+45% +$705K 0.01% 550
2020
Q4 		$1.35M Buy
+10,373
New +$1.39M 0.01% 584
2020
Q1 		– Sell
-1,850
Closed -$213K – 1003
2019
Q4 		$213K Buy
+1,850
New +$184K ﹤0.01% 827
2015
Q1 		– Sell
-5,100
Closed -$495K – 563
2014
Q4 		$495K Buy
+5,100
New +$473K ﹤0.01% 393
2014
Q1 		– Sell
-15,200
Closed -$1.04M – 673
2013
Q4 		$1.04M Buy
+15,200
New +$907K 0.01% 362

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ALNY Position: Q4 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2024, closing a stake of 73,320 shares — an estimated $20.2M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ALNY in Q4 2013 and held it in 11 quarters. The position peaked at $20.2M in Q3 2024. 594 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Alnylam Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 73,320 Alnylam Pharmaceuticals shares in Q4 2024, an estimated $20.2M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Alnylam Pharmaceuticals in Q4 2013 and held it in 11 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Alnylam Pharmaceuticals position peaked at $20.2M in Q3 2024.
  • 594 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2024, filed 10 Feb 2025.